Physician

Jay M Rhee, M.D.

According to 2025 Medicare claims, Jay Rhee, M.D. (NPI: 1568490852) practices hematology/oncology in the Atlanta-Sandy Springs-Roswell, GA market, with the plurality of this provider's patient population coming from Fulton, GA. This provider's primary affiliated billing organization is PIEDMONT CANCER INSTITUTE PC (NPI: 1336180637; TIN: 581761689) and primary practice location at 30318-0922. Rhee is affiliated with the Mission Health Partners, LLC (ACO ID: A2591), participating under the MSSP model.

Rhee's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 590 traditional Medicare patients, billed 142,037 HCPCS/CPT codes, and received $2,883,703 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,211 prescription claims across 203 beneficiaries totaling $3,651,643 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 14 claims. Open Payments data shows 60 records totaling $1,338. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $70,654 to $2,883,703. Similarly, Part D prescription costs have moved sharply higher in recent years, from $830,949 to $3,651,643. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	428	1,222	$70,654
2016	422	1,134	$67,838
2017	432	1,158	$69,705
2018	620	43,328	$555,817
2019	616	121,275	$1,648,231
2020	546	74,777	$1,649,437
2021	564	92,969	$1,653,577
2022	629	143,267	$2,912,400
2023	646	103,211	$2,022,284
2024	590	142,037	$2,883,703

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	118	623	$830,949
2016	123	597	$976,048
2017	112	541	$947,789
2018	215	792	$1,507,612
2019	195	1,085	$2,323,484
2020	177	1,110	$2,939,250
2021	184	990	$3,610,704
2022	198	1,212	$4,799,466
2023	199	1,197	$4,314,037
2024	203	1,211	$3,651,643

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	17	$626
2016	N/R	27	$13,132
2017	13	127	$25,692
2018	14	124	$15,758
2019	N/R	32	$3,173
2020	N/R	N/R	N/R
2021	N/R	12	$1,208
2022	N/R	31	$1,093
2023	N/R	14	$4,808
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	120	352	$92
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	133	555	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	219	444	$57
96372	Injection of drug or substance under skin or into muscle	96	337	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	358	1,127	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	67	1,848	$1,291,434
Pomalyst	Pomalidomide	19	532	$416,891
Imbruvica	Ibrutinib	26	728	$411,532
Kisqali	Ribociclib Succinate	13	392	$198,827
Venclexta	Venetoclax	13	390	$184,420

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	60	$1,338	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jay M. Rhee, M.D.?

Tedicare shows public-source Medicare data for Jay M. Rhee, M.D. (NPI 1568490852), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jay M. Rhee, M.D. have ACO affiliation data?

Jay M. Rhee, M.D. is shown with ACO affiliation data for Mission Health Partners, LLC (MSSP, ACO ID A2591).

What billing organization is linked to Jay M. Rhee, M.D.?

Jay M. Rhee, M.D. is linked to PIEDMONT CANCER INSTITUTE PC (billing NPI 1336180637) in the available physician profile data.

Does Jay M. Rhee, M.D. have Open Payments data?

Jay M. Rhee, M.D. has 60 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.